PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 171 filers reported holding PROTAGONIST THERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is 0.41 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,215 | +61.6% | 72,830 | +167.5% | 0.06% | +72.7% |
| Q2 2023 | $752 | +55.4% | 27,230 | +29.3% | 0.03% | +43.5% |
| Q1 2023 | $484 | -47.3% | 21,060 | -75.0% | 0.02% | -54.9% |
| Q4 2022 | $918 | -99.8% | 84,172 | +18.7% | 0.05% | +41.7% |
| Q3 2022 | $598,000 | -14.2% | 70,932 | -19.5% | 0.04% | -30.8% |
| Q2 2022 | $697,000 | +21.0% | 88,097 | +262.3% | 0.05% | +36.8% |
| Q1 2022 | $576,000 | +206.4% | 24,317 | +56.7% | 0.04% | -44.9% |
| Q2 2019 | $188,000 | +42.4% | 15,517 | +48.0% | 0.07% | -8.0% |
| Q1 2019 | $132,000 | +40.4% | 10,487 | -25.3% | 0.08% | +188.5% |
| Q4 2018 | $94,000 | -79.5% | 14,041 | -68.4% | 0.03% | -73.7% |
| Q3 2018 | $458,000 | +31.2% | 44,477 | -14.3% | 0.10% | +37.5% |
| Q2 2018 | $349,000 | – | 51,907 | – | 0.07% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 2,449,183 | $20,647,000 | 6.08% |
| Bain Capital Life Sciences Investors, LLC | 2,260,572 | $19,057,000 | 2.28% |
| Kynam Capital Management, LP | 519,212 | $4,377,000 | 0.92% |
| RTW INVESTMENTS, LP | 4,176,837 | $35,211,000 | 0.81% |
| Tri Locum Partners LP | 199,500 | $1,682,000 | 0.46% |
| Birchview Capital, LP | 38,000 | $320,000 | 0.22% |
| Gratus Capital, LLC | 206,113 | $1,738,000 | 0.18% |
| FARALLON CAPITAL MANAGEMENT LLC | 3,651,887 | $30,785,000 | 0.17% |
| PDT Partners, LLC | 126,038 | $1,063,000 | 0.16% |
| FOX RUN MANAGEMENT, L.L.C. | 40,683 | $343,000 | 0.13% |